Sodium glucose cotransporter 2 (SGLT2) inhibitors and CKD: Are you a #flozinator?

Authors

Anoushka Krishnan, Royal Perth Hospital, Perth, Australia.
Mythri Shankar, Department of Nephrology, Institute of Nephro-urology, Bengaluru, India.
Edgar V. Lerma, Advocate Aurora Health
Nasim Wiegley, Department of Medicine, University of California, Davis School of Medicine, Sacramento, California.

Recommended Citation

Krishnan A, Shankar M, Lerma EV, Wiegley N; GlomCon Editorial Team. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?. Kidney Med. 2023;5(4):100608. Published 2023 Feb 1. doi:10.1016/j.xkme.2023.100608

Affiliations

Advocate Christ Medical Center

Abstract

Sodium/glucose cotransporter 2 (SGLT2) inhibitors have rapidly emerged as a novel therapy to reduce the rate of progression of chronic kidney disease (CKD). With humble beginnings in the 19th century for treating malaria, this class of drugs initially developed for the treatment of diabetes has now revolutionized the management of heart failure and CKD. SGLT2 inhibitors trigger glucosuria, thus modestly improving glycemic control. In addition, they have pleiotropic effects, such as reducing intraglomerular pressure and improving tubuloglomerular feedback, which lead to their beneficial effects on CKD progression. Recent data from randomized controlled trials have demonstrated the efficacy of this class of drugs in CKD. We briefly review the evidence from major trials on SGLT2 inhibitors in CKD, discuss the mechanisms of action and provide an overview of the safe and successful prescription of these medications.

Document Type

Article

PubMed ID

36915368